<p><em>DCOY 的交易将于 2026 年 1 月 8 日开始</em></p>
<p><em>公司的专有肽结合平台利用人工智能驱动的计算基础设施加速候选药物的选择</em></p>
<p><em>资本高效的 2026 年计划包括将领先的抗病毒药物推进至临床，同时扩展管线和合作机会</em></p>
<p>马萨诸塞州剑桥，2026 年 1 月 7 日（全球新闻通讯）——Salarius Pharmaceuticals, Inc.（纳斯达克：SLRX）（Salarius）宣布将其公司名称更改为 Decoy Therapeutics Inc.（Decoy），其普通股将于 2026 年 1 月 8 日开始在纳斯达克资本市场以 DCOY 的股票代码交易。这些变化反映了公司专注于通过其专有平台开发新型肽结合治疗药物，从而减少药物开发和制造的复杂性。</p>
<p>“更改我们的公司名称是我们转型为开发下一代肽结合治疗药物的又一步，初步重点是高优先级的病毒和肿瘤靶点，” Decoy Therapeutics 的首席执行官 Rick Pierce 表示。“凭借人工智能驱动的发现引擎、一个受到全球健康利益相关者关注的领先抗病毒项目以及紧密聚焦的 2026 年计划，我们有能力将第一个项目推进至临床，扩展我们的管线，并为患者和股东创造长期价值。”</p>
<p>这些变化不会影响已发行股份的总数、股东的权利、CUSIP 号码或过户代理，也不会影响公司的运营或领导层，包括 Decoy 的高级管理团队和 Salarius 的财务团队。</p>
<p><strong>一个为规模、速度和战略合作伙伴关系而构建的平台</strong></p>
<p>Decoy Therapeutics 正在推进一个专有的肽结合平台，旨在选择性拦截和中和高价值生物靶点，初步项目针对全冠状病毒活性和多种病毒威胁，包括流感和 RSV。公司的领先抗病毒项目已吸引了生物医学先进研究与发展局（BARDA）和全球健康组织的战略关注，使 Decoy 能够在数据出现时追求额外的非稀释性赠款资金、合作和未来的发展伙伴关系。</p>
<p>与此同时，Decoy 正在推进下一代发现项目，包括：</p>
<ul>
<li>旨在应对重叠呼吸威胁的多病毒诱饵候选药物</li>
<li>在抗病毒药物之外，对新型 G 蛋白偶联受体（GPCR）靶向药物候选药物进行细胞和类器官级别的验证</li>
</ul>
<p>这些努力旨在支持多个研究性新药（IND）申请及其相关活动、同行评审的出版物和合作讨论，同时保持资本效率和灵活性。</p>
<p><strong>2026 年重点：执行、数据和潜在里程碑</strong></p>
<p>公司的 2026 年优先事项包括：</p>
<ul>
<li>将领先的抗病毒项目推进至监管准备阶段</li>
<li>在多个平台上扩展发现和临床前验证</li>
<li>利用人工智能驱动的计算基础设施加速候选药物的选择</li>
<li>与大型制药公司、技术领袖和学术机构追求战略合作</li>
<li>加强公司的资本结构并扩大投资者的可见度</li>
</ul>
<p>公司相信这种以执行为中心的方法使 Decoy 能够实现多个创造价值的里程碑，同时通过合作和非稀释性资金保留上行潜力。</p>
<p><strong>关于 Decoy Therapeutics Inc.</strong></p>
<p>Decoy 是一家处于临床前阶段的生物技术公司，利用机器学习和人工智能工具以及高速合成技术快速设计、工程和制造针对严重未满足医疗需求的肽结合药物候选者。公司的初步管线专注于呼吸道病毒和胃肠道癌症。Decoy 已吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、谷歌人工智能初创企业计划和 NVIDIA Inception 计划等多个来源的重大资本。公司还获得了由 BARDA 通过 BLUE KNIGHT™提供的 QuickFire Challenge 奖资助，这是强生创新-JLABS 与 BARDA 在战略准备和应对管理局之间的合作。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的关于公司的 “前瞻性声明”，包括对其主要资产的里程碑预期和公司未来前景的展望。这些声明可能会讨论关于未来计划、趋势、事件、运营结果或财务状况的目标、意图和期望，或其他基于公司管理层当前信念的内容，以及管理层所做的假设和当前可获得的信息。前瞻性声明通常包括具有预测性质的声明，并依赖于或提及未来事件或条件，包含诸如 “可能”、“将”、“可以”、“应该”、“会”、“期望”、“预期”、“计划”、“可能”、“相信”、“估计”、“项目”、“打算” 等类似表达。非历史事实的声明即为前瞻性声明。前瞻性声明基于当前的信念和假设，这些信念和假设面临风险和不确定性，并不能保证未来的表现。实际结果可能因各种因素而与任何前瞻性声明中包含的内容有实质性差异，包括但不限于：公司未能获得足够融资以执行其商业计划的风险，以及与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题和 IMP3ACT™平台的潜力，以及公司能否维持其在纳斯达克的上市风险。读者被敦促仔细审查和考虑公司在其向 SEC 提交的报告中所做的各种披露，包括其于 2025 年 8 月 22 日向 SEC 提交的 8-K 表格的当前报告、截至 2024 年 12 月 31 日的财政年度的 10-K 表格年报，以及其 10-Q 表格的季度报告和其他向 SEC 提交的文件。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，公司实际结果可能与预期或预测的结果有实质性差异。</p>
<p><strong>联系方式：</strong></p>
<p><strong>Decoy Therapeutics</strong></p>
<p>Rick Pierce，首席执行官</p>
<p>Pierce@decoytx.com</p>
<p>617-447-8299</p>
<p>Peter Marschel，首席商务官</p>
<p>Peter@Decoytx.com</p>
<p>617-943-6305</p>
<p><strong>投资者和媒体</strong></p>
<p>Alliance Advisors IR</p>
<p>Jody Cain</p>
<p>jcain@allianceadvisors.com</p>
<p>310-691-7100</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1USTNOU00zTXpRNE1qVXhJekl3TVRZM056Yz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1USTNOU00zTXpRNE1qVXhJekl3TVRZM056Yz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY0OTg4YjUtZDViOC00OWNhLWI0MDYtZGQ5N2NlNGM0NWU0LTEwMjgzNTAtMjAyNi0wMS0wNy1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY0OTg4YjUtZDViOC00OWNhLWI0MDYtZGQ5N2NlNGM0NWU0LTEwMjgzNTAtMjAyNi0wMS0wNy1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png"/></p>

SLRX

DCOY

<p>Salarius Pharmaceuticals, Inc. 将于 2026 年 1 月 8 日更名为 Decoy Therapeutics Inc.，纳斯达克股票代码更改为 DCOY。此次品牌重塑反映了公司专注于开发下一代肽偶联疗法的方向。公司旨在推进其领先的抗病毒项目并扩展其产品线，同时利用人工智能进行候选药物的选择。Decoy Therapeutics 计划追求战略合作和非稀释性融资，重点解决呼吸道病毒和胃肠道癌症的问题。这些变化不会影响股份数量或公司运营</p>

<p><em>Trading under DCOY to commence on January 8, 2026</em></p>
<div class="lb-trans"><p><em>DCOY 的交易将于 2026 年 1 月 8 日开始</em></p>
</div><p><em>Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection</em></p>
<div class="lb-trans"><p><em>公司的专有肽结合平台利用人工智能驱动的计算基础设施加速候选药物的选择</em></p>
</div><p><em>Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities</em></p>
<div class="lb-trans"><p><em>资本高效的 2026 年计划包括将领先的抗病毒药物推进至临床，同时扩展管线和合作机会</em></p>
</div><p>CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8, 2026. These changes reflect the Company’s focus on developing novel peptide-conjugate therapeutics through its proprietary platform that reduces the complexity of drug development and manufacturing.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥，2026 年 1 月 7 日（全球新闻通讯）——Salarius Pharmaceuticals, Inc.（纳斯达克：SLRX）（Salarius）宣布将其公司名称更改为 Decoy Therapeutics Inc.（Decoy），其普通股将于 2026 年 1 月 8 日开始在纳斯达克资本市场以 DCOY 的股票代码交易。这些变化反映了公司专注于通过其专有平台开发新型肽结合治疗药物，从而减少药物开发和制造的复杂性。</p>
</div><p>&#34;Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets,&#34; said Rick Pierce, CEO of Decoy Therapeutics. “With an AI-enabled discovery engine, a lead antiviral program of interest to global health stakeholders and a tightly focused 2026 plan, we are positioned to advance our first program into the clinic, expand our pipeline and create long-term value for patients and shareholders.”</p>
<div class="lb-trans"><p>“更改我们的公司名称是我们转型为开发下一代肽结合治疗药物的又一步，初步重点是高优先级的病毒和肿瘤靶点，” Decoy Therapeutics 的首席执行官 Rick Pierce 表示。“凭借人工智能驱动的发现引擎、一个受到全球健康利益相关者关注的领先抗病毒项目以及紧密聚焦的 2026 年计划，我们有能力将第一个项目推进至临床，扩展我们的管线，并为患者和股东创造长期价值。”</p>
</div><p>These changes do not affect the total number of shares outstanding, shareholders’ rights, the CUSIP number or the transfer agent, nor do they impact the Company’s operations or leadership, which includes Decoy’s senior management team and Salarius’ finance team.</p>
<div class="lb-trans"><p>这些变化不会影响已发行股份的总数、股东的权利、CUSIP 号码或过户代理，也不会影响公司的运营或领导层，包括 Decoy 的高级管理团队和 Salarius 的财务团队。</p>
</div><p><strong>A Platform Built for Scale, Speed and Strategic Partnerships</strong></p>
<div class="lb-trans"><p><strong>一个为规模、速度和战略合作伙伴关系而构建的平台</strong></p>
</div><p>Decoy Therapeutics is advancing a proprietary peptide-conjugate platform designed to selectively intercept and neutralize high-value biological targets, with initial programs addressing pan-coronavirus activity and multi-viral threats, including influenza and RSV. The Company’s lead antiviral program has attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning Decoy to pursue additional non-dilutive grant funding, collaborations and future development partnerships as data emerge.</p>
<div class="lb-trans"><p>Decoy Therapeutics 正在推进一个专有的肽结合平台，旨在选择性拦截和中和高价值生物靶点，初步项目针对全冠状病毒活性和多种病毒威胁，包括流感和 RSV。公司的领先抗病毒项目已吸引了生物医学先进研究与发展局（BARDA）和全球健康组织的战略关注，使 Decoy 能够在数据出现时追求额外的非稀释性赠款资金、合作和未来的发展伙伴关系。</p>
</div><p>In parallel, Decoy is advancing next-generation discovery programs, including:</p>
<div class="lb-trans"><p>与此同时，Decoy 正在推进下一代发现项目，包括：</p>
</div><ul>
<li>Multi-virus decoy candidates designed to address overlapping respiratory threats</li>
<li>Cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals</li>
</ul>
<div class="lb-trans"><ul>
<li>旨在应对重叠呼吸威胁的多病毒诱饵候选药物</li>
<li>在抗病毒药物之外，对新型 G 蛋白偶联受体（GPCR）靶向药物候选药物进行细胞和类器官级别的验证</li>
</ul>
</div><p>Together, these efforts are intended to support the filing of multiple investigational new drug (IND) applications and their enabling activities, peer-reviewed publications and partnering discussions, while maintaining capital efficiency and flexibility.</p>
<div class="lb-trans"><p>这些努力旨在支持多个研究性新药（IND）申请及其相关活动、同行评审的出版物和合作讨论，同时保持资本效率和灵活性。</p>
</div><p><strong>2026 Focus: Execution, Data and Potential Milestones</strong></p>
<div class="lb-trans"><p><strong>2026 年重点：执行、数据和潜在里程碑</strong></p>
</div><p>The Company’s priorities for 2026 include:</p>
<div class="lb-trans"><p>公司的 2026 年优先事项包括：</p>
</div><ul>
<li>Advancing lead antiviral programs toward regulatory readiness</li>
<li>Expanding discovery and preclinical validation across multiple platforms</li>
<li>Leveraging AI-enabled computational infrastructure to accelerate candidate selection</li>
<li>Pursuing strategic collaborations with big pharma, technology leaders and academic institutions</li>
<li>Strengthening the Company’s capital structure and expanding investor visibility</li>
</ul>
<div class="lb-trans"><ul>
<li>将领先的抗病毒项目推进至监管准备阶段</li>
<li>在多个平台上扩展发现和临床前验证</li>
<li>利用人工智能驱动的计算基础设施加速候选药物的选择</li>
<li>与大型制药公司、技术领袖和学术机构追求战略合作</li>
<li>加强公司的资本结构并扩大投资者的可见度</li>
</ul>
</div><p>The Company believes this execution-focused approach positions Decoy to achieve multiple value-creating milestones while retaining upside through partnerships and non-dilutive funding.</p>
<div class="lb-trans"><p>公司相信这种以执行为中心的方法使 Decoy 能够实现多个创造价值的里程碑，同时通过合作和非稀释性资金保留上行潜力。</p>
</div><p><strong>About Decoy Therapeutics Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Decoy Therapeutics Inc.</strong></p>
</div><p>Decoy is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program, among other sources. The Company has also received QuickFire Challenge award funding provided by BARDA through BLUE KNIGHT™, a collaboration between Johnson &amp; Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.</p>
<div class="lb-trans"><p>Decoy 是一家处于临床前阶段的生物技术公司，利用机器学习和人工智能工具以及高速合成技术快速设计、工程和制造针对严重未满足医疗需求的肽结合药物候选者。公司的初步管线专注于呼吸道病毒和胃肠道癌症。Decoy 已吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、谷歌人工智能初创企业计划和 NVIDIA Inception 计划等多个来源的重大资本。公司还获得了由 BARDA 通过 BLUE KNIGHT™提供的 QuickFire Challenge 奖资助，这是强生创新-JLABS 与 BARDA 在战略准备和应对管理局之间的合作。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company, including expected achievement of milestones for its lead asset and future prospects of the Company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of the Company, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “can,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform, and the risk that the Company can maintain its listing on Nasdaq. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed with the SEC on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected or projected.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的关于公司的 “前瞻性声明”，包括对其主要资产的里程碑预期和公司未来前景的展望。这些声明可能会讨论关于未来计划、趋势、事件、运营结果或财务状况的目标、意图和期望，或其他基于公司管理层当前信念的内容，以及管理层所做的假设和当前可获得的信息。前瞻性声明通常包括具有预测性质的声明，并依赖于或提及未来事件或条件，包含诸如 “可能”、“将”、“可以”、“应该”、“会”、“期望”、“预期”、“计划”、“可能”、“相信”、“估计”、“项目”、“打算” 等类似表达。非历史事实的声明即为前瞻性声明。前瞻性声明基于当前的信念和假设，这些信念和假设面临风险和不确定性，并不能保证未来的表现。实际结果可能因各种因素而与任何前瞻性声明中包含的内容有实质性差异，包括但不限于：公司未能获得足够融资以执行其商业计划的风险，以及与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题和 IMP3ACT™平台的潜力，以及公司能否维持其在纳斯达克的上市风险。读者被敦促仔细审查和考虑公司在其向 SEC 提交的报告中所做的各种披露，包括其于 2025 年 8 月 22 日向 SEC 提交的 8-K 表格的当前报告、截至 2024 年 12 月 31 日的财政年度的 10-K 表格年报，以及其 10-Q 表格的季度报告和其他向 SEC 提交的文件。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，公司实际结果可能与预期或预测的结果有实质性差异。</p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Decoy Therapeutics</strong></p>
<div class="lb-trans"><p><strong>Decoy Therapeutics</strong></p>
</div><p>Rick Pierce, CEO</p>
<div class="lb-trans"><p>Rick Pierce，首席执行官</p>
</div><p>Pierce@decoytx.com</p>
<div class="lb-trans"><p>Pierce@decoytx.com</p>
</div><p>617-447-8299</p>
<div class="lb-trans"><p>617-447-8299</p>
</div><p>Peter Marschel, CBO</p>
<div class="lb-trans"><p>Peter Marschel，首席商务官</p>
</div><p>Peter@Decoytx.com</p>
<div class="lb-trans"><p>Peter@Decoytx.com</p>
</div><p>617-943-6305</p>
<div class="lb-trans"><p>617-943-6305</p>
</div><p><strong>Investors and Media</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体</strong></p>
</div><p>Alliance Advisors IR</p>
<div class="lb-trans"><p>Alliance Advisors IR</p>
</div><p>Jody Cain</p>
<div class="lb-trans"><p>Jody Cain</p>
</div><p>jcain@allianceadvisors.com</p>
<div class="lb-trans"><p>jcain@allianceadvisors.com</p>
</div><p>310-691-7100</p>
<div class="lb-trans"><p>310-691-7100</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1USTNOU00zTXpRNE1qVXhJekl3TVRZM056Yz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMTI3NSM3MzQ4MjUxIzIwMTY3Nzc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY0OTg4YjUtZDViOC00OWNhLWI0MDYtZGQ5N2NlNGM0NWU0LTEwMjgzNTAtMjAyNi0wMS0wNy1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmY0OTg4YjUtZDViOC00OWNhLWI0MDYtZGQ5N2NlNGM0NWU0LTEwMjgzNTAtMjAyNi0wMS0wNy1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png"/></p>

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics | SLRX Stock News

Salarius Pharmaceuticals 更名为 Decoy Therapeutics，并将其纳斯达克股票代码更改为 DCOY，以体现其对下一代肽偶联疗法的专注 | SLRX 股票新闻